Prehypertension: An Opportunity for a New Public Health Paradigm

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 561-569

  Egan, Brent M ^a   Lackland, Daniel T ^a   Jones, Daniel W ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Cardiovascular disease; Hypertension; Lifestyle change; Pharmacologic therapy; Prehypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

AEROBIC EXERCISE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEALTH PROMOTION; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC DISORDER; PREHYPERTENSION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SODIUM RESTRICTION; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIET, SODIUM-RESTRICTED; DISEASE PROGRESSION; FEMALE; HEALTH BEHAVIOR; HEALTH PROMOTION; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; PREHYPERTENSION; RISK FACTORS; SMOKING CESSATION; SOCIAL RESPONSIBILITY; WEIGHT LOSS;

EID: 77957741009     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.07.008     Document Type: Review

References (63)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the joint national committee on prevention, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
2. Robinson S.C., Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med 1939, 64:409-444.
3. Greenlund K.J., Croft J.B., Mensah G.A. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 2004, 164:2113-2118.
4. Neaton J.D., Kuller L., Stamler J., et al. Impact of systolic and diastolic blood pressure on cardiovascular mortality. Hypertension, pathophysiology, diagnosis, and management 1995, Raven Press, Ltd, New York. 2nd edition. J.H. Laragh, B.M. Brenner (Eds.).
5. Levy R.L., Hillman C.C., Stoud W.D., et al. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945, 129:585-588.
6. Julius S., Schork M.A. Borderline hypertension-a critical review. J Chronic Dis 1971, 23:723-754.
7. Julius S., Jamerson K., Mejia A., et al. The association of borderline hypertension with target organ changes and higher coronary risk. JAMA 1990, 264:354-358.
8. Giles T.D., Berk B.C., Black H.R., et al. Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505-512.
9. Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. NCHS Data Brief, No. 3, 2008.
10. Wang Y., Wang Q.J. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee Guidelines. Arch Intern Med 2004, 164:2126-2134.
11. Qureshi A.I., Suri M.F., Kirmani J.F., et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005, 11:CR403-CR409.
12. USA Quick Facts from the US Census Bureau Available at:, Accessed January 7, 2010. http://quickfacts.census.gov/qfd/states/00000.html.
13. Julius S., Jamerson K., Mejia A., et al. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990, 265:354-358.
14. Eliasson M., Jansson J.H., Nilsson P., et al. Increased levels of tissue plasminogen activator antigen in essential hypertension: a population-based study. J Hypertens 1997, 15:349-356.
15. Toikka J.O., Laine H., Ahotupa M., et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000, 36:929-933.
16. Palombo C., Kozakova M., Magagna A., et al. Early impairment of coronary flow reserve and increase in minimum coronary resistance in borderline hypertensive patients. J Hypertens 2000, 18:453-459.
17. Millgard J., Hagg A., Sarabi M., et al. Endothelium-dependent vasodilation in normotensive subjects with a familial history of essential hypertension and in young subjects with borderline hypertension. Blood Press 2002, 11:279-284.
18. Chrysohoou C., Pitsavos C., Panagiotakos D.B., et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease. The Attica Study. Am J Hypertens 2004, 17:568-573.
19. Knecht S., Wersching H., Lohmann H., et al. High-normal blood pressure is associated with poor cognitive performance. Hypertension 2008, 51:663-668.
20. Sehestedt T., Jeppesen J., Hansen T.W., et al. Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. J Hypertens 2009, 27:1165-1171.
21. Meisinger C., Döring A., Heier M. Blood pressure and risk of type 2 diabetes mellitus in men and women from the general population: the monitoring trends and determinants of cardiovascular diseases/cooperative health research in the region of Augsburg cohort study. J Hypertens 2008, 26:1809-1815.
22. Leitschuh M., Cuppies L.A., Kannel W., et al. High-normal blood pressure progression to hypertension in the Framingham Study. Hypertension 1991, 17:22-27.
23. Winegarden C.R. From " prehypertension" to hypertension? Additional evidence. Ann Epidemiol 2004, 15:720-725.
24. Julius S., Nesbitt S.D., Egan B.M., et al. Feasiblity of treating prehypertension with an angiotensin receptor blocker. N Engl J Med 2006, 354:1685-1697.
25. Vasan R.S., Larson M.G., Leip E.P., et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682-1686.
26. Julius S., Kaciroti N., Nesbitt S., et al. TROPHY revisited: outcomes based on the JNC 7 definition of hypertension. J Agric Saf Health 2008, 2:39-43.
27. Lüders S., Schraderr J., Jürgen B., et al. The PHARAO study: prevention of hypertension with angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008, 26:1487-1496.
28. Vasan R.S., Larson M.G., Leip E.P., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
29. Liszka H.A., Mainous A.G., King D.E., et al. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005, 3:294-299.
30. Kshirsagar A.V., Carpenter M., Bang J., et al. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006, 119:133-141.
31. Egan B.M. Should metabolic syndrome patients with prehypertension receive antihypertensive therapy?. Therapeutic strategies in hypertension 2006, 9-25. Clinical Publishing, Oxford (UK), Chapter 2. G.L. Bakris (Ed.).
32. Zhang Y., Lee E.T., Devereux R.B., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006, 47:410-414.
33. Ogden L.G., He J., Lydick E., et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000, 35:539-543.
34. Hsia J., Margolis K.L., Eaton C.B., et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007, 115:855-860.
35. Tsai S.P., Wen C.P., Chan H.T., et al. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract 2008, 82:148-156.
36. Nesbitt S.N., Julius S., Leonard D., et al. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY Study. Am J Hypertens 2005, 18(7):979-984.
37. Lasser V.I., Raczynski J.M., Stevens V.J., et al. Trial of prevention, phase II: structure and content of the weight loss and dietary sodium reduction interventions. Ann Epidemiol 1995, 5:156-164.
38. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med 1997, 157:657-667. The Trials of Hypertension Prevention Collaborative Research Group.
39. Hjermann I., Holme I., Vlve B.K., et al. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo study group of a randomised trial in healthy men. Lancet 1981, 2(8259):1303-1310.
40. Hjermann I. Smoking and diet intervention in healthy coronary high risk men. Methods and 5-year follow-up of risk factors in a randomized trial. The Oslo study. J Oslo City Hosp 1980, 30:3-17.
41. Moser M. A decade of progress in the management of hypertension. Hypertension 1983, 5:808-813.
42. Goldman L., Cook F. The decline in ischemic heart disease mortality rates: an analysis of the comparative effective of medical interventions and changes in lifestyle. Ann Intern Med 1984, 101:825-836.
43. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336:1117-1124.
44. Esposito K., Marella R., Ciotaola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. JAMA 2004, 292:1440-1446.
45. Katzmarzyk P.T., Church T.S., Blair S.N. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004, 164:1092-1097.
46. The Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
47. Fung T.T., Chiuve S.E., McCullough M.L., et al. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008, 168:713-720.
48. Ford E.S., Zhao G., Li C., et al. Trends in obesity and abdominal obesity among hypertensive and nonhypertensive adults in the United States. Am J Hypertens 2008, 21:1124-1128.
49. Mellen P.B., Gao S.K., Vitolins M.Z., et al. Deteriorating dietary habits among adults with hypertension. DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Arch Intern Med 2008, 168:308-314.
50. Merill R.M., Timmreck T.C. Introduction to epidemology 2006, Jones and Barlett Publishers, Sadbury (MA), p. 128, Fig. 5.11. 4th edition.
51. Cordain L., Eaton S.B., Sebastian A., et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005, 81:341-345.
52. Booth F.W., Laye M.J., Lees S.J., et al. Reduced physical activity and risk of chronic disease: the biology behind the consequences. Eur J Appl Physiol 2008, 102:381-390.
53. Kennedy E.T. Evidence for nutritional benefits in prolonging wellness. Am J Clin Nutr 2006, 83:410S-414S.
54. Huckabee M. Quit digging your grave with a knife and fork: a 12-stop program to end bad habits and begin a healthy lifestyle. Center Street 2005, Time Warner Book Group, New York.
55. Davenport C, Brown E. The Washington Post, Girding for an uphill battle for recruits: obesity, poor education make many younger people unfit for military. Nov. 5, 2009.
56. Rosendorff C., Black H.R., Cannon C.P., et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 2007, 50:e28-e55.
57. Bobrie G., Chatellier G., Genes N., et al. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly hypertensive patients. JAMA 2004, 291:1342-1349.
58. Mancia G., Facchetti R., Bombelli M., et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006, 47:846-853.
59. Tunis S.R., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290:1624-1632.
60. Luce B.R., Kramer J.M., Goodman S.N., et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009, 151:206-209.
61. Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. The expert panel. Arch Intern Med 1988, 148:36-69.
62. Wong N.D., Pio J.R., Franklin S.S., et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421-1426.
63. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.